- ►bloodjournal.org [PDF] RT Silver, SH Woolf, R Hehlmann, FR … - Blood, 1999 - Am Soc Hematology . Hematology; all rights reserved Copyright 2007 by The American Society of DC
20036. by the American Society of Hematology, 1900 M St, NW, Suite 200,
Washington Blood (print ISSN 0006-4971, online ISSN 1528-0020), is ... Cited by 309 - Related articles - BL Direct - All 9 versions
- ►bloodjournal.org F Bonifazi, A de Vivo, G Rosti, F Guilhot, J … - Blood, 2001 - Am Soc Hematology Treatment of Philadelphia-positive (Ph + ) chronic myeloid leukemia (CML) with
interferon- (IFN- ) was introduced in the early 1980s, 1-3 was developed and
expanded at the MD Anderson Hospital, Houston, TX, 4 , 5 but did not become ... Cited by 188 - Related articles - BL Direct - All 6 versions
HM Kantarjian, S O'Brien, P Anderlini, M … - BLOOD-NEW YORK-, 1996 - bloodjournal.hematologylibrary.org . reserved Hematology; all rights Copyright 2007 by The American Society of
Suite 200, Washington DC 20036. semimonthly by the American Society of
Hematology, 1900 M St, NW, Blood (print ISSN 0006-4971, online ISSN ... Cited by 177 - Related articles - View as HTML - BL Direct - All 8 versions
JE Cortes, M Talpaz, H Kantarjian - The American journal of medicine, 1996 - Elsevier PJ Pialkow, SM Gartler and A Yoshida, Clonal origin of chronic myelocytic
leukemia in man, Proc Natl Acad Sci USA 58 (1967), pp. 1468–1471. ... PC
Nowell and DA Hungerford, Chromosome studies on normal and leukemic human ... Cited by 127 - Related articles - BL Direct - All 8 versions
HM Kantarjian, FJ Giles, SM O'Brien, M … - Hematology/oncology clinics of North America, 1998 - Elsevier The prognosis for patients with chronic myelogenous leukemia (CML) has changed
markedly since 1856, when the use of arsenicals (Fowler's solution) was first
advocated in this condition. 154 In the early 1900s, systemic or splenic ... Cited by 71 - Related articles - BL Direct - All 5 versions
- ►haematologica.com [PDF] AM Carella, F Frassoni, J Melo, C Sawyers, C … - Haematologica, 1997 - haematologica.org Background and Objective. From the discovery of the Ph-chromosome, there has
been an extraordinary progress in our understanding of chronic myeloid leukemia
(CML). During the last three decades, new findings arising from dissection ... Cited by 50 - Related articles - BL Direct - All 15 versions
- ►annals.org MW Kattan, Y Inoue, FJ Giles, M Talpaz, H … - Annals of internal medicine, 1996 - Am Coll Physicians Design: A decision analysis and Markov model that described the natural history
of the therapeutic process. The Markov model contained two treatment arms
(interferon- and hydroxyurea) and eight states of health (complete ... Cited by 43 - Related articles - BL Direct - All 4 versions
J Cortes, H Kantarjian, S O'Brien, LE … - The American journal of medicine, 1996 - Elsevier Patients with CML aged 60 years and older included in all protocols with IFN-α
therapy for early chronic phase CML at the MD Anderson Cancer Center were
analyzed. They were treated with human leukocyte or recombinant human ... Cited by 38 - Related articles - BL Direct - All 5 versions
R Hehlmann, H Ansari, J Hasford, H Heimpel, … - British journal of haematology, 1997 - interscience.wiley.com Survival times in chronic myeloid leukaemia (CML) may vary widely depending on
the risk profiles of patients. This fact is frequently not, or not sufficiently,
considered in evaluating survival in CML, and some studies do not report ... Cited by 36 - Related articles - BL Direct - All 4 versions
- ►ascopubs.org [PDF] NL Liberato, S Quaglini, G Barosi - Journal of Clinical Oncology, 1997 - jco.ascopubs.org Purpose: To evaluate the cost-effectiveness of inter- fer)on al(IFNa) treatment
of patients with chronic my- elogenous leukemia relative to conventional chemo-
therapy. Materials and Methods: A decision-analysis model that involved a ... Cited by 32 - Related articles - BL Direct - All 6 versions
